. 2016 Sep 29;11(9):e0163652. doi: 10.1371/journal.pone.0163652

Table 2. Results of 31 patients with EGFR mutation(s) and response to tyrosine kinase inhibitor.

Pt. #	Primary tumor		EBUS diagnosed LN		TKI, sequence	Response to TKI
Pt. #	Exon	Mutation	Exon	Mutation	TKI, sequence	Response to TKI
1	19	Deletion (E746_A750del)	19	Deletion (E746_A750del)	Gefitinib, 3^rd	PR
2	19	Deletion (L747_S751del)	19	Deletion (L747_S751del)	Gefitinib, 2^nd	PR
3	19	Deletion (E746_P753del)	19	Deletion (E746_P753del)	None
4	19	Deletion (E746_A750del)	19	Deletion (E746_A750del)	Gefitinib, 1^st	SD
5	19	Deletion (E746_S752del)	19	Deletion (E746_S752del)	Gefitinib, 1^st	PR
6	19	Deletion (E746_A750del)	19	Deletion (E746_A750del)	Gefitinib, 1^st	PR
7	19	Deletion (L747_A750del)	19	Deletion (L747_A750del)	Erlotinib, 2^nd	PR
8	19	Deletion (L747_T751del)	19	Deletion (L747_T751del)	Erlotinib, 2^nd	PR
9	19	Deletion (E746_A750del)	19	Deletion (E746_A750del)	None
10	19	Deletion (L747_S752del)	19	Deletion (L747_S752del)	Erlotinib, 1^st	PR
11	19	Deletion(L747_S751del)	19	Deletion (L747_S751del)	Gefitinib, 1^st	PR
11	18	G719S			Gefitinib, 1^st	PR
12	19	Deletion (E746_A750del)		WT	Erlotinib,1^st	PR
13	19	Deletion (E746_A750del)		WT	Gefitinib, 1^st	PR
14	21	L858R	21	L858R	Gefitinib, 1^st	PD
15	21	L858R	21	L858R	Gefitinib, 2^nd	PD
16	21	L858R	21	L858R	Gefitinib, 1^st	PR
17	21	L858R	21	L858R	Gefitinib, 1^st	PR
18	21	L858R	21	L858R	Gefitinib,1^st	PR
19	21	L858R	21	L858R	Gefitinib,1^st	PR
20	21	L858R	21	L858R	Gefitinib,1^st	PR
21	21	L858R	21	L858R	Gefitinib,1^st	PR
22	21	L858R	21	L858R	Gefitinib, 2^nd	PD
22			20	T790M	Gefitinib, 2^nd	PD
23	21	L858R	21	L858R	None
23	20	S718I	20	T790M	None
24	21	L858R,	21	L858R	Erlotinib, 1^st	PR
24	20	S784F			Erlotinib, 1^st	PR
25	21	L858R		WT	Gefitinib, 1^st	PD
26	20	Insertion (D770_N771ins)	20	Insertion (D770_N771ins)	Erlotinib, 3^rd	PD
27	20	Insertion (V770_D771ins)	20	Insertion(D770_N771ins)	Gefitinib, 1^st	SD
28	20	Insertion(A763_Y764ins)			None
28	18	K714N	18	K714N	None
29	18	Deletion (E709<T910>D)	18	Deletion (E709<T910>D)	Gefitinib, 1^st	PD
30	19	L747P	19	L747P	Gefitinib, 2^nd	PD
31	21	R776H,	21	R776H	None
31	20	L861Q			None

LN; lymph node, WT; wild type, TKI; tyrosine kinase inhibitor, PR; partial response, SD; stable disease, PD; progressive disease